These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11201293)

  • 1. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention.
    Cuendet M; Pezzuto JM
    Drug Metabol Drug Interact; 2000; 17(1-4):109-57. PubMed ID: 11201293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoxygenase metabolism: roles in tumor progression and survival.
    Pidgeon GP; Lysaght J; Krishnamoorthy S; Reynolds JV; O'Byrne K; Nie D; Honn KV
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):503-24. PubMed ID: 17943411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A causal relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism.
    Marks F; Müller-Decker K; Fürstenberger G
    Toxicology; 2000 Nov; 153(1-3):11-26. PubMed ID: 11090944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
    Li N; Sood S; Wang S; Fang M; Wang P; Sun Z; Yang CS; Chen X
    Clin Cancer Res; 2005 Mar; 11(5):2089-96. PubMed ID: 15756036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of COX and LOX by curcumin.
    Rao CV
    Adv Exp Med Biol; 2007; 595():213-26. PubMed ID: 17569213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
    Attiga FA; Fernandez PM; Weeraratna AT; Manyak MJ; Patierno SR
    Cancer Res; 2000 Aug; 60(16):4629-37. PubMed ID: 10969817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
    Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
    Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eicosanoid regulation of angiogenesis in tumors.
    Nie D; Honn KV
    Semin Thromb Hemost; 2004 Feb; 30(1):119-25. PubMed ID: 15034803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer.
    Ding XZ; Tong WG; Adrian TE
    Pancreatology; 2001; 1(4):291-9. PubMed ID: 12120207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
    Kashfi K; Rigas B
    Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent development in the field of dual COX / 5-LOX inhibitors.
    Julémont F; Dogné JM; Pirotte B; de Leval X
    Mini Rev Med Chem; 2004 Aug; 4(6):633-8. PubMed ID: 15279597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of eicosanoids in prostate cancer progression.
    Nie D; Che M; Grignon D; Tang K; Honn KV
    Cancer Metastasis Rev; 2001; 20(3-4):195-206. PubMed ID: 12085962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arachidonic acid metabolites of the lipoxygenase as well as the cyclooxygenase pathway may be involved in regulating preadipocyte differentiation.
    Shillabeer G; Kumar V; Tibbo E; Lau DC
    Metabolism; 1998 Apr; 47(4):461-6. PubMed ID: 9550546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenases and lipoxygenases in prostate and breast cancers.
    Nie D
    Front Biosci; 2007 Jan; 12():1574-85. PubMed ID: 17127404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
    Shureiqi I; Chen D; Lotan R; Yang P; Newman RA; Fischer SM; Lippman SM
    Cancer Res; 2000 Dec; 60(24):6846-50. PubMed ID: 11156377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?
    Fürstenberger G; Krieg P; Müller-Decker K; Habenicht AJ
    Int J Cancer; 2006 Nov; 119(10):2247-54. PubMed ID: 16921484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer.
    Ding XZ; Hennig R; Adrian TE
    Mol Cancer; 2003 Jan; 2():10. PubMed ID: 12575899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention.
    Cathcart MC; Lysaght J; Pidgeon GP
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):363-85. PubMed ID: 22134655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.